Investigación sobre el cáncer

<p>Applications Triterpenoid which can inhibit the proliferation of leukemia HL-60 cells.<br>References Cho, J., et al.: Pulmon. Pharmacol. Ther., 23, 190 (2010), Gohil, V., et al.: Nat. Biotechnol., 28, 249 (2010), Saha, S., et al.: J. Agric. Food Chem., 58, 434 (2010),<br></p>

<p>Applications Benz[a]anthracen-3-ol is a derivative of the most potent carcinogenic hydrocarbon, 7,12-Dimethylbenz[a]anthracene (D464500), a highly potent carcinogen that is activated by microsomal enzymes to a diol epoxide metabolite that binds covalently to DNA in mammalian cells, leading ultimately to tumor induction. Benz[a]anthracen-3-ol is used in carcinogenesis studies relating to breast cancer.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Harvey, R. et al.: J. Org. Chem., 69, 2024 (2004); Harvey, R. et a;.: J. Med. Chem., 31, 154 (1988); Lee. H. et al.: J. Org. Chem., 51, 3501 (1986); Huggins, C., et al.: Proc. Nat. Acad. Sci. U.S.A., 58, 2253 (1967), Dipple, A., et al.: N. Cancer Res., 43, 4123 (1983);<br></p>

<p>Applications A metabolite of Temozolomide, an antineoplastic.<br></p>

<p>Applications A novel semi-synthetic taxane with antitumor activity used for the treatment of castration-resistant prostate cancer. A microtubule inhibitor.<br>References Agarwal, N. et al.: Fut. Oncol., 7, 15 (2011); Mita, A. et al.: Clin. Cancer Res., 15, 723 (2009); Figg, W.D. et al.: Cancer Biol. Ther., 10, 1233 (2010);<br></p>

<p>Applications Methyltriphenylphosphonium Bromide is a lipophilic molecule with a cation allowing for it to be used to deliver molecules to specific cell components. Also considered an antineoplastic agent.<br>References Selassie, C.D. et al.: J. Med. Chem., 33, 1914 (1990); Venkatachalam, M.A et al.: Kidney Int., 49, 449 (1996);<br></p>

<p>Applications An oleic acid synthetic analog that is an effective non-toxic anticancer drug with a wide spectrum against different types of cancer. An antihypertensive.<br>References Llado, V. et al.: J. Cell. Molec. Med., 14, 659 (2010); Alemany, R. et al.: J. Lip. Res., 47, 1762 (2006); Martinez, J. et al.: J. Pharmacol. Exp. Therap., 315, 466 (2005);<br></p>

<p>Stability Hygroscopic, Temperature Sensitive<br>Applications Gemcitabine Triphosphate is a phosphorylated metabolite of Gemcitabine (G305000), an antineoplastic agent.<br>References Kennedy., E.P., et al.: J. Biol. Chem., 222, 193 (1956),<br></p>

<p>Stability Hygrscopic<br>Applications N1,N12-Diacetylspermine Dihydrochloride is a diacetylated derivative of Spermine (S680510) and is recognized as a novel tumor marker in patients with breast and colorectal cancers.<br>References Kato, M., et al.: Anticancer Res., 34, 3053 (2014); Umemori, Y., et al.: Clin. Chim. Acta, 411, 1894 (2010); Kawakita, M., et al.: J. Biochem., 139, 315 (2006); Hiramatsu, K., et al.: Clin. Cancer Res., 11, 2986 (2005)<br></p>

<p>Impurity Irinotecan USP Related Compound E<br>Applications An anticancer drug, showed strong activity against various murine tumors. A Camptothecin (CPT) derivative as antineoplastic agent against drug-resistant tumors. Irinotecan USP Related Compound E.<br>References Brangi, M., et al.: Cancer Res., 59 5938 (1999), Miyake, K., et al.: Cancer Res., 59, 8 (1999) , Bom, D., et al.: J. Med. Chem., 43, 3970 (2000) , Gamcsik, M., et al.: Mol. Cancer Ther., 1, 11 (2001).<br></p>

<p>Stability Light Sensitive<br>Applications β-Cembrenediol is an inhibitor of tumor promotion. Novel c-Met inhibitors which are used in anticancer treatments.<br>References Le-Huu, P. et al.: ChemCatChem., 8, 3755 (2016); Ebrahim, H. et al.: Bioorg. Med. Chem., 24, 5748 (2016);<br></p>

<p>Applications Principal pigment of bile and constituent of many biliary calculi.<br>References Stenhagen, R., et al.: Biochem. J., 33, 1591 (1939), Gray, et al.: J. Chem. Soc., 2264, 2268 (1961),<br></p>

<p>Stability Light Sensitive<br>Applications N-Desmethyl (E)-α-Hydroxy Tamoxifen is a N-demethylated, α-Hydroxyated metabolite of Tamoxifen (T006000).<br>References Poon, G.K. et al.: Drug Metab.Dispos. 23,377 (1995); Teunissen, S.F. et al.: J. Pharmac. Biomed. Anal., 55, 518 (2011); Muerdter, T.E. et al.: Clin. Pharmacol. Therap., 89, 708 (2011);<br></p>